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ABSTRACT 
Background: Diabetic men have lowered overall risk of prostate cancer (PCa), but the role of 
hyperglycemia is unclear. In this cohort study we estimated PCa risk among men with diabetic 
fasting blood glucose level. 
Methods: Participants of the Finnish Randomized Study of Screening for Prostate Cancer 
(FinRSPC) were linked to laboratory database for information on glucose measurements since 
1978. The data was available for 17,860 men. Based on the average yearly level men were 
categorized as normoglycemic, prediabetic or diabetic. Median follow-up was 14.7 years. 
Multivariable-adjusted Cox regression was used to calculate hazard ratios (HRs) and 95% 
confidence intervals (95%CIs) for prostate cancer overall and separately by Gleason grade and 
metastatic stage. 
Results: In total 1,663 PCa cases were diagnosed. Compared to normoglycemic men, men with 
diabetic blood glucose level had increased risk of PCa (HR 1.52; 95% CI 1.31-1.75). The risk 
increase was observed for all tumor grades, and persisted for a decade afterwards. Antidiabetic drug 
use removed the risk association. Limitations include absence of information on lifestyle factors and 
limited information on BMI.  
Conclusions: Untreated diabetic fasting blood glucose level may be a prostate cancer risk factor. 
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INTRODUCTION 
The relationship between established type 2 diabetes mellitus (DM) and different types of cancer 
has been investigated broadly. Studies have shown that people with DM have lower risk of 
developing prostate cancer (PCa) compared with non-diabetics (1,2). This may be due to altered 
hormone milieu in diabetic men or lower prostate-specific antigen (PSA) leading to less prostate 
biopsies due to elevated PSA. However, it is not clear whether this concerns also poorly 
differentiated PCa, as some studies have suggested that the risk could be elevated (3). Glucose 
metabolism may have an independent role in prostate cancer development and progression (4,5). 
There is evidence that hyperglycaemia and poor glycemic control and the related hyperinsulinaemia 
could be the possible links (6-8). Yet there are very few studies concentrating on connections 
between PCa and blood glucose levels and glycemic control, and the results from available studies 
are conflicting. Some have reported increased risk of advanced or aggressive PCa among men with 
higher glucose levels (9), while other studies have reported a protective association between 
hyperglycemia and PCa (4,10). Indirect support for the role of hyperglycemia as PCa risk factor 
comes from studies reporting lowered risk among men using antidiabetic drugs, particularly 
metformin (11). 
In this study we investigated the associations between fasting blood glucose and glycemic control 
(glycated haemoglobin, HbA1c) and PCa risk overall and by Gleason grade and tumor stage in a 
cohort of men participating in The Finnish Randomized Study of Screening for Prostate Cancer 
(FinRSPC) (12), the largest component of European Randomized Study of Screening for Prostate 
Cancer (ERSPC) (13). The main goal of FinRSPC and ERSPC studies was to find out if systematic 
screening can decrease prostate cancer mortality. A significant reduction in PCa mortality was 
observed in the ERSPC study, though with overdiagnosis of well-differentiated prostate cancer. In 
the FinRSPC study the reduction in PCa mortality was smaller and not statistically significant (12). 
MATERIALS AND METHODS 
Study cohort 
The Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) is the largest 
component of the multinational European Study of Prostate Cancer Screening (ERSPC) (13).  In the 
FinRSPC, all men aged 55-67 from Tampere and Helsinki residential areas were identified between 
1996 and 1999. After exclusion of prevalent prostate cancer cases identified from national Finnish 
Cancer Registry, a total of 80,144 men were randomly assigned either to be screened with PSA at 
four-year intervals (the screening arm, 31,866 men) or to control arm with no intervention and 
followed through national registries (48,278 men). The screening finished in 2008, but the follow-
up for cancer cases in this study extended until the end of 2014. The available information on 
prostate cancers were obtained trough study database or through The Finnish Cancer Registry for 
men in the control arm. The information included date of diagnosis, tumor Gleason score and tumor 
stage at diagnosis, recorded in this study as non-metastatic (all M0 cases) and metastatic (all M1 
cases). 
The Finnish Cancer Registry is a nationwide registry collecting information of cancer diagnoses 
from all Finnish health care units and pathology laboratories through mandatory notifications. The 
registry covers more than 99% of all cancer cases diagnosed in Finland (14).  
To obtain information on BMI the participants of the third screening round during 2004-2008 were 
mailed surveys asking height and weight along with the screening invitations (15). This information 
was available for 11,698 men in the FinRSPC cohort. 
The study cohort was linked to a nationwide prescription database of the Social Insurance 
Institution (SII) of Finland. The SII is a governmental agency providing reimbursements for the cost 
of physician-prescribed drugs to all Finnish citizens. From this database we obtained information on 
usage of prescribed antidiabetic drugs, antihypertensive drugs, statins, NSAIDs and aspirin during 
1995-2009. Information on over-the-counter drug purchases or on drugs administered during 
hospital inpatient periods was not available. 
 
Information on blood glucose level and glycated haemoglobin 
The information on results from each measurement of fasting plasma or blood glucose level and 
glycated haemoglobin (HbA1c) performed at the Pirkanmaa region were obtained from the Fimlab 
database and linked to the study cohort by using individual identifier number. The data was 
available from 1978 for fasting blood glucose level and from 1991 for HbA1c. Information 
considering indication of blood glucose measurements was not available, but it is most likely that 
these measurements are a mix of standard health checks, age-dependent health checks and control 
measurements of diabetic men.  
Fimlab Laboratories is one of the leading laboratory companies in Finland (16). Fimlab provides 
laboratory services, education and research in Pirkanmaa, Central Finland and Tavastia regions. A 
major part of laboratory measurements in the Pirkanmaa region are done in Fimlab laboratories. 
Approximately 25% of the FinRSPC participants lived at Pirkanmaa region at baseline. 
The study population of the FinRSPC study was linked to the Fimlab database to identify men with 
at least one available measurement of blood glucose and/or HbA1c during 1978-2015. The 
information on fasting glucose levels and/or HbA1c levels were available for 19,263 men, thus 
forming the cohort of this study (Supplementary figure).  The information on fasting glucose levels 
or HbA1c levels were available for 17,860 and 11,736 men, respectively. Each measured fasting 
glucose level was divided into three categories: normoglycemic if fasting glucose level was under 
or equal to 6.0 mmol/l measured from plasma or under or equal to 5.5 mmol/l measured from blood; 
pre-diabetic if glucose level was between 6.0 and 7.0 mmol/l (plasma) or between 5.6 and 6.1 
mmol/l (blood) and diabetic if glucose level was over 7.0 mmol/l (plasma) or over 6.1 mol/l 
(blood). The HbA1c levels were also divided into three categories: normoglycemic if HbA1c was 
under 39 mmol/mol or under 5.7%, prediabetic if HbA1c was between 39 and 47mmol/mol or 
between 5.7 and 6.4%, and diabetic if HbA1c level was over 47mmol/mol or over 6.4%.  
 
 
Statistical analysis 
We used Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence 
intervals (CIs) for overall risk of prostate cancer by fasting glucose and HbA1c levels. Analyses for 
Gleason 6 or less, Gleason 7-10, non-metastatic and metastatic tumors were performed separately. 
These separate analyses were carried out in the same way as the overall analysis, but we only 
included those PCa cases that met the specific criteria, and calculated hazard ratios between 
different groups for that cancer type. The follow-up commenced from the FinRSPC randomization 
(baseline) and ended at the date of death, diagnosis of prostate cancer, emigration or end of the 
follow-up time (31 December 2014), whichever came first. The time axis was years and month 
since the baseline. The model was adjusted for age only (age-adjusted analysis) and further for the 
FinRSPC study arm and the use of antihypertensive drugs, cholesterol-lowering drugs, NSAIDs and 
aspirin (multivariable-adjusted model). 
For each calendar year we calculated the average yearly fasting glucose and HbA1c levels based on 
all measurements within that year. Fasting glucose level and HbA1c were analyzed as time-
dependent variables, updated separately for each year after the baseline. All men who did not have 
any glucose or HbA1c measurement available in certain year was assigned to separate missing- 
category for that year. 
We further calculated the average blood glucose levels both before and after initiation of 
antidiabetic drug use, i.e. the first recorded purchase of any antidiabetic drug. Fasting glucose level 
before and after antidiabetic drug use was analyzed as time-independent variables. 
 The association between fasting glucose level and prostate cancer risk in subgroups was evaluated 
by repeating the analyses after stratifying the study population by background variables. Subgroup 
analyses were stratified by use of drugs that are associated with metabolic syndrome and chronic 
inflammation. We tested effect modification by adding an interaction term between blood glucose 
level and the effect modifier into the Cox regression model. The interaction term was considered 
statistically significant if the p-value was ≤ 0.05. 
The temporal association between fasting glucose level and prostate cancer risk was evaluated by 
performing separate lag time analysis for measurements done five, ten, fifteen and twenty years 
earlier. 
We used IBM SPSS statistics software (version 23) to perform Cox regression analyses. All p-
values are two-sided.  
 
Ethics approval of the study 
The study has been approved by the ethics committee of the Pirkanmaa Hospital District, decision 
number R10167. 
  
RESULTS 
Population characteristics 
Of the 17,860 men, 8,481 were normoglycemic, 5,812 were at the pre-diabetic range and 3,567 men 
were at the diabetic range of fasting glucose (Table 1). During the median follow-up of 14.7 years 
after the baseline, a total of 1,663 prostate cancers were diagnosed in the study cohort, 808 in the 
normoglycemic group, 454 in the pre-diabetic group and 401 in the diabetic group. Median BMI in 
the diabetic group was non-significantly higher compared to the normoglycemic group.  
The use of cholesterol-lowering drugs, antihypertensive drugs and aspirin was more common in the 
diabetic group compared to the normoglycenic or pre-diabetic group. However, use of NSAIDs and 
5α-reductase inhibitors was less common in the diabetic group (Table 1). 
Median PSA was lower among diabetic men in all three FinRSPC screening rounds compared to 
normoglycemic men (Table 1). 
Fasting blood glucose, HbA1c and prostate cancer risk 
Compared to the normoglycemic men, overall PCa risk was elevated in diabetic, but not in pre-
diabetic men; multivariable adjusted HR 1.52; 95% CI 1.31-1.75 (Table 2). The risk was similarly 
elevated regardless of tumor Gleason score. However, the risk elevation was limited to non-
metastatic tumors; fasting blood glucose level was not associated with risk of metastatic prostate 
cancer (Table 2). Association between HbA1c levels and PCa risk was not statistically significant. 
However, the number of men in these analyses was low. 
 
Effect modification by background variables 
The connection between fasting glucose level and PCa risk was affected by several background 
variables (Figure 1). Diabetic blood glucose level was associated with increased risk in the 
FinRSPC screening arm but not in the control arm (p for interaction < 0.001). The risk association 
was also modified by the use of antihypertensive drugs; the association was weaker in users of these 
drugs (p for interaction 0.018). Further, use of antidiabetic drugs generally and in separate analysis 
metformin use abolished the risk association (p for interaction < 0.001).  No clear effect 
modification by 5-ARI use was observed, either (p for interaction 0.78). 
Similar risk modifications were observed also for Gleason score 8-10 tumors (Figure 2). However, 
the interactions were not statistically significant in this subgroup. 
 
Role of change in fasting glucose levels after initiation of antidiabetic drug use 
Changes in fasting blood glucose levels after the initiation of antidiabetic drug use were not 
associated with changes in prostate cancer risk (Table 3). Similarly, no change in prostate cancer 
risk was observed by changes in fasting glucose levels after initiation of metformin use. 
 
Long-term effects of fasting glucose levels 
Blood glucose level measured 10 years earlier was borderline significantly associated with elevated 
PCa risk as in our main analysis; diabetic fasting glucose level was associated with increased risk of 
non-metastatic tumors and Gleason 6 or less tumor (Table 4). Similar, albeit non-significant risk 
increase were observed also with 15-year lag time. However, no risk associations were observed for 
the blood glucose levels measured two decades earlier. 
  
DISCUSSION 
 
In this study we observed an association between fasting blood glucose level and elevated prostate 
cancer risk. This association was more noticeable in the screening arm, and concerned both poorly 
and well-differentiated cancers. Previous studies suggest that diabetes mellitus and use of 
antidiabetic drugs are associated with lowered overall prostate cancer risk, while the risk of high-
grade tumors may be elevated (17-20). Our findings do not support the risk lowering association for 
diabetes as a condition, as diabetic fasting blood glucose levels were associated with increased, not 
lowered prostate cancer risk. This supports role of hyperglycemia as prostate cancer risk factor. 
Nevertheless, use of antidiabetic drugs abolished the risk increase observed with diabetic fasting 
blood glucose level. Therefore our study indirectly supports anticancer effects of antidiabetic drugs, 
but the mechanism of action is probably unrelated to blood glucose levels.  
Some previous studies have reported association between diabetes and lowered PSA compared to 
non-diabetic men (21-23). Concordantly, median PSA was lower also in our study. This would 
presumably lead to lower incidence of PCa, as fewer prostate biopsies would be performed due to 
PSA elevation. In a setting of prostate cancer screening this would mean lower PCa incidence 
among diabetic men especially in the FinRSPC screening arm. In contrast, we observed a stronger 
association with increased PCa risk in the FinRSPC screening arm, which suggests that prostate 
cancer incidence among diabetic men is higher compared to non-diabetic men even if the median 
PSA is lower. The risk elevation seems to apply to all tumor grades as the risk elevation was 
observed also for high-grade tumors.  
A previous meta-analysis of 14 epidemiological studies found increased risk of several cancer types 
for elevated HbA1c, excluding prostate cancer (4). Concordantly, we did not observe risk 
associations with HbA1c, only with fasting blood glucose levels. 
Another previous study has examined the association between blood glucose and prostate cancer 
risk. (24). In this case-cohort study of 500 participants insulin concentrations and glucose 
concentrations were determined from a single overnight fasting serum sample 5 to 12 years before 
prostate cancer diagnosis. The study suggests an association between PCa risk and elevated fasting 
serum insulin, but not with elevated glucose levels. In contrast to our study, the observed blood 
glucose levels were mainly in the normal range, and no diabetic blood glucose levels were 
observed. Thus our results are in concordance with this previous study, as we did not observe any 
risk increase even in men with pre-diabetic blood glucose level, only among men at diabetic glucose 
level. 
The significance of blood glucose as PCa risk factor is supported by our earlier findings in which 
we found connection between changes in genes associated to glucose metabolism and PCa risk (5).  
Previously reported lower PCa risk among men with diabetes could be explained by use of 
antidiabetic medication; for example lower PCa risk has been reported among metformin users (25-
28). In this study the use of antidiabetic drugs abolished the observed association between high 
blood glucose levels and elevated risk of prostate cancer. This supports that the treatment of 
diabetes could remove the risk increase associated with hyperglycemia. However, the changes in 
blood glucose level after initiation of antidiabetic drug use during the follow-up was not connected 
to PCa risk, which suggests that the possible antitumor effects of antidiabetic drugs are mediated 
through mechanisms other than blood glucose control. However, confirmation will be needed from 
other studies as confidence intervals were relatively wide in our risk estimates. 
The association between blood glucose level and PCa risk is likely to be long-term, because the 
elevated risk was observable also for the fasting blood glucose level measured a decade earlier. This 
suggests that diabetic glucose level could increase the risk of initiation of prostate cancer 
development. To our knowledge this is the first study to examine long-term associations between 
fasting blood glucose and prostate cancer risk. 
However, we did not observe risk associations by HbA1c level, which reflects long-term glucose 
balance. HbA1c results were available for fewer participants than were fasting glucose 
measurements, thus these analyses were limited by lowered statistical power. Nevertheless, this 
difference between the risk associations between HbA1c and fasting glucose suggests that the 
interaction between blood glucose, insulin and prostate cancer may be complex. 
Strengths of our study include large population-based cohort and information on blood glucose 
measurements starting from the 1980’s. We were also able to evaluate the effect of antidiabetic drug 
on the risk association through comprehensive national prescription database free of recall bias. 
The study also has some limitations. We had no information on lifestyle factors, such as smoking, 
diet or physical activity, which could possible affect prostate cancer risk and cause confounding 
(29-31). The available information on BMI was also limited. Because of these factors, residual 
confounding is possible. Also, because we had no information on the indication of blood glucose 
measurements, selection bias is possible affecting the generalizability of our results. However, it 
does not limit our comparisons by blood glucose level because all men with blood glucose 
measurements available are prone to the same selection. Our study population is almost entirely 
Caucasian due to homogeneity of the Finnish population; thus our results may not be generalizable 
to other ethnicities. 
In conclusion, diabetic fasting blood glucose level is associated with elevated PCa risk in a 
population-based cohort of Finnish men, especially in the setting of systematic PSA-based 
screening. The risk association is long-term, observed a decade in advance of the diagnosis.  Use of 
antidiabetic drugs removes the risk association, supporting the risk lowering effect of these drugs. 
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 FIGURE LEGENDS 
 
Figure 1. Association between overall prostate cancer risk and blood glucose level in 
subgroup analysis. Study cohort of 17,860 men from the Finnish Randomized Study 
of Screening for Prostate Cancer. Pre-D = pre-diabetic, D = diabetic blood glucose 
level. * P for interaction = 0.229 for pre-diabetic, p < 0.001 for diabetic men. ** P 
for interaction = 0.435 for pre-diabetic, p = 0.018 for diabetic men. *** P for 
interaction = 0.153 for pre-diabetic, p < 0.001 for diabetic men. NSAID = non-
steroidal anti-inflammatory drugs, ASA= acetylsalicylic acid. 
 
Figure 2. Association between Gleason 8-10 prostate cancer risk and blood glucose 
level in subgroup analysis. Study cohort of 17,860 men from the Finnish 
Randomized Study of Screening for Prostate Cancer. Pre-D = pre-diabetic, D = 
diabetic blood glucose level. NSAID = non-steroidal anti-inflammatory drugs, ASA= 
acetylsalicylic acid. 
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Men participating in the FinRSPC study (80,144) 
All men who had at least one fasting blood / plasma glucose and / or HbA1C-measurement taken (19,263) - Screening arm: 7,359 - Control arm: 11,868 
Study population linked to the Fimlab database. 
Men with HbA1C-measurements (11,736) -  Screening arm: 4,491 -  Control arm: 7,245 
Men with glucose measurements (17,860) 
- Screening arm: 6,085 
- Control arm: 11,055 
Supplementary Figure. Flow chart for forming of the study population. Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer with at least one fasting blood/plasma glucose measurement available during 1978-2014. 
Table 1. Population characteristics. Study cohort of 17,860 men from the Finnish Randomized Study of 
Screening for Prostate Cancer with at least one fasting blood/plasma glucose measurement available 
during 1978-2014. 
 Average fasting blood glucose level during follow-up 
 Normoglycemic Pre-diabetic Diabetic 
n of men 8,481 5,812 3,567 
FinRSPC study arm    
Screening; n (%) 3,154 (37.2) 2,253 (38.8) 1,398 (39.2) 
Control; n (%) 5,327 (62.8) 3,559 (61.2) 2,169 (60.8) 
Median (IQR) follow-up 17.0 (15.1-18.0) 16.3(13.8-18.0) 15.3(7.1-17.0) 
n of PCa cases 808 454 401 
Total follow-up time 
(person years) 
130,811 87,400 43,779 
PCa incidence / 1000 
person years 
6.18 5.19 9.16 
Gleason score; n (%)    
6 or less 409 (50.6) 215 (47.4) 203 (50.6) 
7-10 384 (47.5) 230 (50.7) 189 (47.1) 
Missing 15 (1.9) 9 (2.0) 9 (2.2) 
Tumor stage; n (%)    
Localized 759 (93.9) 410 (90.3) 374 (93.3) 
Metastatic 48 (5.9) 44 (9.7) 25 (6.2) 
Missing 1 (0.1) 0 (0.0) 2 (0.5) 
Median (IQR) PSA1 in    
1st screening round 1.02 (0.62-1.76) 0.97 (0.61-1.69) 1.01 (0.58-2.06) 
P for difference* Ref 0.21 0.47 
2nd screening round 1.30 (0.77-2.28) 1.23 (0.72-2.26) 1.16 (0.66-2.31) 
P for difference* Ref 0.13 0.01 
3rd screening round 1.43 (0.81-2.49) 1.39 (0.77-2.41) 1.19 (0.67-2.24)) 
P for difference* Ref 0.11 < 0.001 
Median (IQR) BMI  26.0 (24.2-28.3) 27.7 (25.3-30.6) 28.6 (26.2-31.6) 
Antidiabetic medication 
use; n(%)2 
207 (2.4) 1,370 (23.6) 2,376 (66.6) 
P for difference** Ref <0.001 <0.001 
Statin use; n(%) 3,291 (38.8) 2,708 (46.6) 1,851 (51.1) 
P for difference** Ref <0.001 <0.001 
Antihypertensive drug 
use; n (%) 
5,481 (64.6) 4,387 (75.5) 2,917 (81.8) 
P for difference** Ref <0.001 <0.001 
NSAID use; n (%) 6,845 (80.7) 4,692 (80.7) 2,749 (77.0) 
P for difference** Ref 0.98 <0.001 
ASA use; n (%) 1,536 (18.1) 1,159 (19.9) 715 (20.0) 
P for difference** Ref 0.006 0.013 
5α-reductase inhibitor 
use; n (%) 
1,253 (14.8) 724 (12.5) 384 (10.8) 
P for difference** Ref <0.001 <0.001 
 
* P  for difference compared to the normoglycemic group. Calculated with chi-square test. 
** P  for difference compared to the normoglycemic group. Calculated with Mann-Whitney U- test. 
1  All PSA values measured are from men in the screening arm of the study 
2 Categorization based on average blood glucose level, thus also users of antidiabetic drugs may be 
included in the normoglycemic group if they have good blood glucose control
Table 2. Prostate cancer risk by average fasting blood glucose and HbA1c level. Study cohort of 17,860 men from the Finnish Randomized Study of 
Screening for Prostate Cancer. 
  Prostate cancer risk 
  Overall Gleason 6 or less Gleason 7-10 Localized PCa Metastatic 
 n of 
men/PCa 
cases 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multivar.-
adjusted* 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multivar.-
adjusted* 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multivar.-
adjusted* 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multivar.-
adjusted* 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multivar.-
adjusted* 
 Fasting blood glucose 
level 
         
Normal 8,481/808 Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref 
Pre-
diabetic 
5,812/454 1.07 
(0.99-1.23) 
1.09 
(0.95-1.26) 
1.03 
(0.84-1.27) 
1.08 
(0.95-1.26) 
1.09 
(0.89-1.34) 
1.10 
(0.90-1.36) 
1.10 
(0.94-1.27) 
1.13 
(0.97-1.31) 
0.75 
(0.43-1.31) 
0.74 
(0.42-1.30) 
Diabetic 3,567/401 1.36 
(1.19-1.56) 
1.52 
(1.31-1.75) 
1.26 
(1.04-1.53) 
1.48 
(1.21-1.81) 
1.38 
(1-13-1.70) 
1.46 
(1.18-1.81) 
1.39 
(1.21-1.61) 
1.57 
(1.35-1.82) 
0.99 
(0.58-1.69) 
0.94 
(0.54-1.64) 
 HbA1c level          
Normal 3,978/431 Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref 
Pre-
diabetic 
4,342/338 1.13 
(0.88-1.44) 
1.15 
(0.90-1.47) 
1.07 
(0.75-1.54) 
1.11 
(0.77-1.59) 
1.17 
(0.83-1.64) 
1.18 
(0.84-1.66) 
1.13 
(0.87-1.46) 
1.16 
(0.89-1.50) 
1.05 
(0.42-2.62) 
1.08 
(0.43-2.70) 
Diabetic 2,880/323 0.95 
(0.73-1.23) 
1.04 
(0.80-1.35) 
0.77 
(0.53-1.13) 
0.89 
(0.60-1.31) 
1.08 
(0.75-1.53) 
1.11 
(0.77-1.59) 
0.87 
(0.67-1.15) 
0.96 
(0.73-1.26) 
1.77 
(0.73-4.30) 
1.83 
(0.74-4.52) 
 
* Multivariable-adjusted analyses adjusted with age, the FinRSPC study arm and use of antihypertensive drugs, statins, NSAIDs or aspirin.
Table 3. Impact of change in fasting blood glucose level after initiation of antidiabetic drug use. Study 
cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer. 
 
 
* Multivariable-adjusted analyses adjusted with age, the FinRSPC study arm and use of antihypertensive 
drugs, statins, NSAIDs or aspirin. 
 
 
 
 
  
 Prostate cancer risk 
  Overall Gleason 6 or 
less 
Gleason 7-10 Localized 
PCa 
Metastatic 
 n of 
men/PCa 
cases 
HR (95% 
CI)multivar.-
adjusted* 
HR (95% 
CI)multivar.-
adjusted* 
HR (95% 
CI)multivar.-
adjusted* 
HR (95% 
CI)multivar.-
adjusted 
HR (95% 
CI)multivar.-
adjusted* 
Change in fasting blood glucose level     
No change 427/43 Ref Ref Ref Ref Ref 
Decrease 873/45 0.82 
(0.49-1.36) 
0.85 
(0.39-1.84) 
0.74 
(0.37-1.47) 
0.67 
(0.38-1.20) 
2.87 
(0.87-9.50) 
Increased 933/41 0.83 
(0.55-1.26) 
1.07 
(0.59-1.93) 
0.62 
(0.34-1.13) 
0.85 
(0.54-1.29) 
0.92 
(0.23-3.68) 
Table 4. Association between the fasting blood glucose level 5, 10, 15 and 20 years earlier and prostate cancer risk. Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer. Prostate cancer risk 
 Overall Gleason 6 or less Gleason 7-10 Localized PCa Metastatic 
 HR (95% CI) multivar.-adjusted’ HR (95% CI) multivar.-adjusted’ HR (95% CI) multivar.-adjusted’ HR (95% CI) multivar.-adjusted’ HR (95% CI) multivar.-adjusted’ Average fasting blood glucose level 5 years earlier Normal Ref Ref Ref Ref Ref Pre-diabetic 0.91 (0.70-1.17) 0.71 (0.47-1.07) 1.09 (0.78-1.52) 0.89 (0.68-1.17) 1.08 (0.47-2.50) Diabetic 1.00 (0.78-1.27) 0.63 (0.42-0.94) 1.37 (1.01-1.88) 0.96 (0.74-1.17) 1.25 (0.56-2.76) Average fasting blood glucose level 10 years earlier Normal Ref Ref Ref Ref Ref Pre-diabetic 1.27 (0.78-1.90) 0.63 (0.26-1.52) 1.70 (0.98-2.92) 1.16 (0.73-1.86) 1.97 (0.44-8.82) Diabetic 1.34 (0.93-1.93) 1.62 (0.97-2.69) 1.31 (0.67-1.91) 1.41 (0.97-2.04) 0.38 (0.04-3.42) Average fasting blood glucose level 15 years earlier Normal Ref Ref Ref Ref Ref Pre-diabetic 0.81 (0.34-1.92) 0.62 (0.14-2.68) 0.93 (0.32-2.76) 0.79 (0.31-2.05) 1.07 (0.12-9.59) Diabetic 1.03 (0.58-1.82) 1.52 (0.70-3.27) 0.58 (0.23-1.50) 1.22 (0.68-2.20) - Average fasting blood glucose level 20 years earlier Normal Ref Ref Ref Ref Ref Pre-diabetic 0.30 (0.04-2.20) 0.65 (0.08-5.07) - 0.32 (0.04-2.35) - Diabetic 0.97 (0.41-2.32) - 1.78 (0.68-4.67) 0.90 (0.36-2.26) 1.51 (0.15-37.8) * Multivariable-adjusted analyses adjusted with age, the FinRSPC study arm and use of antihypertensive drugs, statins, NSAIDs or aspirin.  
